Cleveland Clinic Abu Dhabi: A New Era of Cardiac Excellence

By HEOR Staff Writer

November 5, 2023

A Landmark Achievement in Healthcare

The Department of Health – Abu Dhabi (DoH) has declared Cleveland Clinic Abu Dhabi, a component of the M42 network, as a Centre of Excellence (CoE) for Adult Cardiac Surgery (ACS). This significant announcement is a testament to Abu Dhabi’s commitment to delivering world-class healthcare services to its community and reinforces its standing as a leading healthcare destination.

Centre of Excellence for Adult Cardiac Surgery: A New Standard in Cardiac Care

As an ACS CoE, Cleveland Clinic Abu Dhabi offers a comprehensive range of cardiac surgery and structural heart disease interventions. These services are provided by a team of highly experienced cardiologists and some of the world’s most reputable surgeons. The Clinic boasts dedicated cardiac surgery ICU facilities and cardiac operating rooms, supported by core services that include multidisciplinary cardiovascular medicine, interventional cardiology, electrophysiology, and a pioneering structural heart programme.

H.E. Dr. Noura Al Ghaithi, Undersecretary of the DoH, emphasised the importance of the CoE programme in elevating healthcare outcomes and increasing competitiveness across the sector. She expressed delight at the announcement and looked forward to the continuous contributions from partners to enhance the healthcare sector’s excellence.

Hasan Jasem Al Nowais, Chairman of Cleveland Clinic Abu Dhabi and Managing Director and Group Chief Executive Officer of M42, highlighted the Clinic’s establishment as a regional and global benchmark for complex care. He reiterated their commitment to excellence and the vision of providing world-class complex care to patients in the UAE and across the region.

Reference url

Recent Posts

NICE Endorses Rozanolixizumab for Myasthenia Gravis Treatment

By João L. Carapinha

May 1, 2026

Rozanolixizumab myasthenia gravis treatment has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on to standard care for adults with generalised myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosi...
Accelerating Biotechnology Patient Access in Europe Through Strategic Policy Reforms
The biotechnology patient access gap in Europe remains a critical challenge despite the continent’s scientific excellence. The EU Biotech Act offers a strategic opportunity to accelerate the delivery of advanced therapies — such as radioligand, cell and gene, and RNA-based treatments — from disco...
Insulin Substitution Portugal: Implications of Novo Nordisk’s Discontinuation
INFARMED has informed healthcare professionals about the upcoming discontinuation of several Novo Nordisk insulin products in Portugal and to provide clear guidance on insulin substitution Portugal. On 30 April 2026, INFARMED issued Circular 045/CD/100.20.200 announcing that Novo Nordisk Portu...